Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22434857 | 0.83 | KDM4E (0.47) | HPGDKDM4ESMN1; SMN2NPY5RALDH1A1 | |
| SCHEMBL1068923 | 0.81 | KDM4E (1.00) | HPGDKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL724250 | 0.81 | NPY5R (0.72) | HPGDKDM4ESMN1; SMN2NPY5RHPGDS | |
| SCHEMBL28019466 | 0.79 | SMN1; SMN2 (0.44) | HPGDKDM4ESMN1; SMN2NPY5RALDH1A1 | |
| SCHEMBL15676723 | 0.79 | KDM4E (0.44) | HPGDKDM4ESMN1; SMN2SMPD3CYP1A2 | |
| SCHEMBL5204729 | 0.79 | NPY5R (0.54) | HPGDKDM4ESMN1; SMN2NPY5RALDH1A1 | |
| SCHEMBL16713033 | 0.79 | KDM4E (0.44) | HPGDKDM4ESMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL27758763 | 0.79 | KDM4E (0.63) | HPGDKDM4ESMN1; SMN2CYP1A2POLB | |
| SCHEMBL12961547 | 0.79 | KDM4E (0.63) | HPGDKDM4ESMN1; SMN2CYP1A2POLB | |
| SCHEMBL12961556 | 0.79 | KDM4E (0.63) | HPGDKDM4ESMN1; SMN2CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226858-B1 | IMIDAZOLE-BASED ANTIMICROBIAL AGENTS | PROCOMCURE BIOTECH GMBH (AT) | 2021-02-03 | — | — | EP | disclosed |
| CN-109069461-A | The treatment method of illness relevant to marrow source property inhibition cell | 洛克菲勒大学 | 2018-12-21 | — | — | CN | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170368032-A1 | Imidazole-Based Antimicrobial Agents | PROCOMCURE BIOTECH GMBH (AT) | 2017-12-28 | — | — | US | disclosed |
| US-20170334887-A1 | Imidazole-Based Antimicrobial Agents | PROCOMCURE BIOTECH GMBH (AT) | 2017-11-23 | — | — | US | disclosed |
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-15 | — | — | US | disclosed |
| US-9617224-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2275105-B1 | Heterocyclic derivatives as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-05 | — | — | EP | disclosed |
| US-20150259297-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-17 | — | — | US | disclosed |
| US-9079860-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-14 | — | — | US | disclosed |
| CN-102236259-A | Radiation sensitivity resin composition for display element, interlayer insulation film, protective film and spacer and forming method thereof | JSR CORP | 2011-11-09 | — | — | CN | disclosed |
| EP-1499313-B1 | HETEROCYCLIC DERIVATIVES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-29 | — | — | EP | disclosed |
| EP-2275105-A1 | Heterocyclic derivatives as opioid receptor modulators | Janssen Pharmaceutica NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-7659402-B2 | use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7659402-B2 | use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-20070246134-A1 | Phenylnaphthylimidazole Compound and Usage of the Same | SHIKOKU CHEMICALS CORPORATION (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070246134-A1 | Phenylnaphthylimidazole Compound and Usage of the Same | SHIKOKU CHEMICALS CORPORATION (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-7202381-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | HPGD 1339/4885KDM4E 988/4885SMN1; SMN2 4322/4885 |
| US-20170334887-A1 | Imidazole-Based Antimicrobial Agents | TLR5, NISCH, SLC11A2 | HPGD 594/4885KDM4E 2893/4885SMN1; SMN2 3607/4885 |
| US-20150259297-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | HPGD 1339/4885KDM4E 988/4885SMN1; SMN2 4322/4885 |
| US-20070246134-A1 | Phenylnaphthylimidazole Compound and Usage of the Same | CYP1A1, CYP1A2, P4HA1 | HPGD 918/4885KDM4E 2124/4885SMN1; SMN2 2576/4885 |
| US-20070105900-A1 | Pharmaceutical compounds | AURKA, AURKC, CDK1 | HPGD 1931/4885KDM4E 1274/4885SMN1; SMN2 4245/4885 |
| US-20170368032-A1 | Imidazole-Based Antimicrobial Agents | TLR5, NISCH, SLC11A2 | HPGD 594/4885KDM4E 2893/4885SMN1; SMN2 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.